P38MAP kinase inhibitors for use in the relief of cytokine release syndrome associated with cancer immunotherapy
Patent Information
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- POOLBEG PHARMA (UK) LTD
- Filing Date
- 2024-01-12
- Publication Date
- 2026-07-08
AI Technical Summary
Current cancer immunotherapy treatments, such as CAR T cell therapy, often result in cytokine release syndrome (CRS), which is a severe side effect that can be life-threatening and requires reactive treatment after its onset, lacking effective prophylactic measures.
Administering a p38 MAP kinase inhibitor prior to the onset of CRS to inhibit cytokine release by T cells, monocytes, and endothelial cells, thereby preventing or reducing the severity of CRS symptoms and enhancing T cell anti-cancer efficacy.
The p38 MAP kinase inhibitor effectively prevents or reduces CRS symptoms, maintains or enhances T cell anti-cancer efficacy, and mitigates the risk of severe inflammatory responses without impairing core immune function, allowing outpatient administration.